ArticleJournal of inflammation research2025
Effects of Eosinophilopoietins and C-C Chemokines on Chemotaxis, Adhesion, and ROS Production of Blood Eosinophil Subtypes in Asthma Patients.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Two distinct blood eosinophil subtypes have recently been described as inflammatory-like (iEOS-like) and resident-like (rEOS-like) eosinophils. Eosinophilopoietins - interleukin (IL)-3, IL-5, and GM-CSF, as well as C-C chemokines - CCL11, CCL24, and CCL26 (eotaxin-1, 2, 3), CCL5 (RANTES), are key regulators of eosinophil activity. However, our understanding of the effects of these cytokines on blood eosinophil subtype chemotaxis, adhesion, and reactive oxygen species (ROS) production in asthma is limited. Patients and Methods: The study enrolled 13 patients with non-severe allergic asthma (AA), 12 patients with severe eosinophilic asthma (SEA), and 10 healthy subjects (HS). Additionally, AA patients underwent bronchial allergen challenge with Results: In all groups, IL-3, IL-5, and GM-CSF enhanced iEOS-like cells' chemotaxis, ROS production, and adhesion to ASMC, with no impact on rEOS-like cell chemotaxis, and only GM-CSF promoted rEOS-like cell adhesion. SEA patients' rEOS-like cells' ROS production following activation with eosinophilopoietins was higher compared to the AA group. Allergen-activated AA patients' blood eosinophil subtypes' ROS production was further upregulated by IL-3, IL-5, and GM-CSF, Conclusion: Eosinophilopoietins and C-C chemokines increase chemotaxis, adhesion, and ROS production of blood eosinophil subtypes, notably in asthma patients. GM-CSF and CCL26 are the most potent promoters of eosinophil chemotaxis and adhesion, particularly of iEOS-like cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.